Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aprepitant

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Aprepitant. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-003512-22 Sponsor Protocol Number: 0869-130 Start Date*: 2006-11-23
    Sponsor Name:Laboratoires Merck Sharp & Dohme-Chibret
    Full Title: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nau...
    Medical condition: Chemotherapy-induced Nausea and Vomitting
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001156-22 Sponsor Protocol Number: DDD16APREPITANT Start Date*: 2016-07-19
    Sponsor Name:KU Leuven - Drug Delivery and Disposition
    Full Title: The gastrointestinal behavior of aprepitant in healthy volunteers
    Medical condition: healthy human volunteers (administration of an drug against nausea and vomiting
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002029-40 Sponsor Protocol Number: 1001 Start Date*: 2013-08-23
    Sponsor Name:Karolinska Institutet
    Full Title: Aprepitant – effect and safety in treatment of atopic dermatitis
    Medical condition: Atopic Dermatitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001761-42 Sponsor Protocol Number: 0869-131 Start Date*: 2006-06-12
    Sponsor Name:Merck & Co., Inc
    Full Title: A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the ...
    Medical condition: Postoperative Nausea and Vomiting
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036238 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000410-38 Sponsor Protocol Number: LP0066-1019 Start Date*: 2013-10-25
    Sponsor Name:LEO Pharma A/S
    Full Title: Topical Aprepitant in Prurigo Patients (iTAPP) An exploratory phase IIa trial with topically applied aprepitant in patients with prurigo
    Medical condition: Prurigo can present either with hyperkeratotic nodules as prurigo nodularis or without nodules as Prurigo simplex. The disease is characterised by intensely pruritic, lichenified, or excoriated pap...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004603-78 Sponsor Protocol Number: MK-0869-097-02 Start Date*: 2015-02-13
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Preventio...
    Medical condition: chemotherapy induced nausea and vomiting
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-006006-27 Sponsor Protocol Number: 0869-219 Start Date*: 2012-11-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Aprepitant in Pediatric Patients for th...
    Medical condition: Post Operative Nausea and Vomiting in surgical patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10036901 Prophylaxis against postoperative nausea and vomiting LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) CZ (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-003783-30 Sponsor Protocol Number: EME-163-LOR-0025-I Start Date*: 2005-04-27
    Sponsor Name:Technical Unversity of Munich
    Full Title: Application of Aprepitant as salvage prophylaxis after failure of a conventional antiemetic therapy during moderately emetogenic chemotherapy in gastrointestinal cancer
    Medical condition: Chemotherapy-induced nasuea and vomiting (CINV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004953-24 Sponsor Protocol Number: 20041202 Start Date*: 2005-07-20
    Sponsor Name:Department of Anesthesiology, University Hospital Erlangen
    Full Title: A double-blind placebo-controlled two period crossover study of pregabalin and aprepitant in the electrical hyperalgesia model of central sensitisation in healthy volunteers
    Medical condition: The primary aim of the present study is therefore to investigate the effects of oral pregabalin and aprepitant on experimentally-induced central sensitization in the electrical hyperalgesia model, ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003178-17 Sponsor Protocol Number: 0869-148 Start Date*: 2009-01-19
    Sponsor Name:Merck & Co., Inc.
    Full Title: Estudio multicéntrico de 2 partes para evaluar la farmacocinética, la seguridad y la tolerabilidad del aprepitant en pacientes pediátricos sometidos a una intervención quirúrgica. A Multicenter, 2-...
    Medical condition: Prevención de nauseas y vómitos postoperatorios en pacientes pediátricos. Prevention of Postoperative nausea and vomiting in pediatric patients.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036901 Prophylaxis against postoperative nausea and vomiting LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000651-16 Sponsor Protocol Number: 0869-208 Start Date*: 2011-07-20
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention...
    Medical condition: Pediatric Chemotherapy induced nausea and vomiting (CINV)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10017947 - Gastrointestinal disorders 10052401 Vomiting post chemotherapy LLT
    13.1 10017947 - Gastrointestinal disorders 10056989 Nausea post chemotherapy LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) PT (Not Authorised) LT (Completed) ES (Completed) NL (Completed) DK (Completed) HU (Completed) SI (Completed) GR (Completed) GB (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-003311-26 Sponsor Protocol Number: 77839 Start Date*: 2021-11-18
    Sponsor Name:Prinses Máxima Centrum
    Full Title: DAVINCY trial: optimal Duration of (fos)aprepitant prophylaxis for nausea and Vomiting INduced by ChemotherapY in children: a double-blind placebo-controlled crossover randomized phase III trial’
    Medical condition: prolonged anti emetic treatment
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005515-10 Sponsor Protocol Number: 0869-134 Start Date*: 2009-01-22
    Sponsor Name:Merck & Co., Inc
    Full Title: "Estudio multicéntrico, abierto, de 5 partes para evaluar la farmacocinética, seguridad y tolerabilidad del aprepitant y de la dimeglumina de fosaprepitant en pacientes pediátricos que reciben quim...
    Medical condition: Nauseas y vómitos inducidos por quimioterapia Chemotherapy induced nausea and vomiting (CINV)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056989 Nausea post chemotherapy LLT
    9.1 10036899 Prophylaxis against chemotherapy induced vomiting LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) DE (Prematurely Ended) FR (Completed) Outside EU/EEA HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003347-73 Sponsor Protocol Number: UMCN-AKF 07.02 Start Date*: 2007-12-04
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: A pharmacokinetic evaluation of the addition of Aprepitant to the Cisplatin - Etoposide (CE) treatment of patients with metastatic lung carcinoma (ACE).
    Medical condition: Nausea and vomiting after using moderate emetogenic cytostatics such as etoposide and cisplatin for the treatment of patients with metastatic lung carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056989 Nausea post chemotherapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000139-28 Sponsor Protocol Number: 12_DOG07_146 Start Date*: 2013-03-22
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: A single arm double-blind placebo controlled cross-over trial of Aprepitant for the treatment of cough in lung cancer: “CALC” Trial
    Medical condition: Cough relating to lung cancer
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10025044 Lung cancer LLT
    15.1 10038738 - Respiratory, thoracic and mediastinal disorders 10011224 Cough PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000839-21 Sponsor Protocol Number: DREPADOL Start Date*: 2019-06-17
    Sponsor Name:Centre Hospitalier Intercommunal de Créteil
    Full Title: Evaluation of the efficacy and safety of aprepitant in the management of vaso-occlusive crisis in sickle cell children: randomized, single-center, randomized, phase IIb/III prospective study
    Medical condition: vaso-occlusive crisis for patients with sickle cell disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10040644 Sickle cell disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2007-004043-30 Sponsor Protocol Number: 0517-017 Start Date*: 2008-01-08
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of I...
    Medical condition: Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated with Cisplatin Chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054133 Prophylaxis of nausea and vomiting LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) IT (Completed) HU (Completed) PT (Completed) PL (Completed) NL (Completed) LT (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002641-39 Sponsor Protocol Number: PALO-05-01 Start Date*: 2006-10-17
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Open-Label Pilot Study to Evaluate the Efficacy of Palonosetron Associated with Aprepitant (Emend) and Dexamethasone in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy (HEC)
    Medical condition: This is a Phase 4, open-label, pilot study to evaluate the Efficacy of Plaonosetron associated with Aprepitant (Emend) and Dexamethasone in preventing nausea and vomitting in chemotherapy-naïve pat...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004956-38 Sponsor Protocol Number: EmNa Start Date*: 2005-06-06
    Sponsor Name:Gerlinde Egerer (MD); Internal Medicine, Department V
    Full Title: Randomised, placebo controlled, single-center, double-blind clinical trial to investigate efficacy and safety of Aprepitant combined with Kevatril and Dexamethasone versus Placebo combined with Kev...
    Medical condition: multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003367-40 Sponsor Protocol Number: 2007/049/HP Start Date*: 2009-03-03
    Sponsor Name:CHU de Rouen
    Full Title: Pilot study of the effect of a substance P antagonist, aprepitant, on aldosterone and cortisol secretions in healthy volunteers
    Medical condition: The aim is to measure plasma aldosterone and cortisol concentrations in basal conditions and in response to different stimulation tests of the adrenal function
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 18:40:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA